Rapid Build of HIV Related Protective Barriers

Viral Suppression of HIV Infection Clinical Trial

Official title:

Cohort Study on Appropriate Strategies of The Rapid Build of HIV Related Protective Barriers in Yunnan, China

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03852849
• Other study ID #: 2018ZX10721102-002
• Status: Not yet recruiting
• Phase: N/A
• Start date: March 1, 2019
• Est. completion date: March 1, 2021

Study information

• Verified date: February 2019
• Source: National Center for AIDS/STD Control and Prevention, China CDC
• Contact: Zhao Yan, PHD
• Phone: +86-10-5338-0980
• Email: zhaoyan[@]chinaaids.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to screen the optimal intervention strategies to rapid establish the protective barriers against HIV-infection by maximally decreasing the viremia among HIV- infected patients.

Description:

Sexual transmission became the primary route of HIV transmission in China and heterosexual transmission also contributed greatly to HIV epidemic which was mostly reported in South-west rural areas. In past years, Yunnan has experienced powerful campaign of scaling-up the HIV identification as well as antrertroviral therapy.

This study will investigate how to reach the last two of HIV'90-90-90 targets': to provide antiretroviral therapy (ART) for 90% of who diagnosed HIV infection and to achieve viral suppression for 90% of those treated.

The study population consists of participants who received an newly diagnosed HIV infection within the study period. All rerolled participants will be randomized into different study group. In intervention group, medical institutions will provide patients personal involved intervention strategies which guided by frequent viral load detection, and providing of the dosage form of 400 mg EFV in their antiviral therapy.

Main assessment measures are viral suppression rate of HIV-infected patients and treatment coverage .

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 600
• Est. completion date: March 1, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV-positive participants who received an newly diagnosed HIV infection within the study period

• Having a current residential address inside of pilot site limits

• Eighteen years old or above

• HIV transmission is heterosexual contact

Exclusion Criteria:

• IDU

• Having severe mental disorder

Related Conditions & MeSH terms

• HIV Infections
• Viral Suppression of HIV Infection

Intervention

Behavioral:
• Personal involved intervention strategies
Medical institutions will provide personal involved intervention strategies for patients which guided by viral load testing monthly until viral load drop below the detection limit.

Drug:
• The dosage of 400mg EFV
The dosage of 400mg EFV will be used in the antiviral therapy.

Locations

Country	Name	City	State
China	Lincang Center for Disease Control and Prevention	Lincang	Yunnan
China	Wenshan Center for Disease Control and Prevention	Wenshan	Yunnan

Sponsors (3)

Lead Sponsor	Collaborator
National Center for AIDS/STD Control and Prevention, China CDC	Yunnan AIDS Care Center, Yunnan Center for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Viral suppression of HIV-infected patients		12 months
Secondary	Treatment coverage		12 months